Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Teradata Corp
TDC
5
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 1.01M | 111K | 50K | 0 | 852K | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --1.01M | --111K | --50K | --0 | --852K | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | 3.01M | 567K | 845K | 380K | 1.22M | 0 | 0 | 0 | 0 | 0 |
Gross profit | -1.99M | -456K | -795K | -380K | -363K | 0 | 0 | 0 | 0 | 0 |
Operating expense | -25.13%22.23M | -29.68%4.24M | -27.48%6.58M | -18.51%6.02M | -25.16%5.39M | -2.53%29.69M | -24.90%6.02M | 4.87%9.08M | 7.86%7.38M | 3.82%7.2M |
Selling and administrative expenses | -13.78%11.03M | -20.94%2.24M | -7.64%3.18M | -3.21%3.11M | -24.33%2.5M | 11.59%12.8M | -1.53%2.83M | -1.94%3.44M | 17.52%3.21M | 40.99%3.31M |
Research and development costs | -33.73%11.2M | -37.44%2M | -39.60%3.4M | -30.30%2.91M | -25.86%2.89M | -11.06%16.89M | -37.96%3.19M | 9.52%5.64M | 1.43%4.17M | -15.18%3.89M |
Operating profit | 18.42%-24.22M | 22.11%-4.69M | 18.72%-7.38M | 13.37%-6.4M | 20.12%-5.75M | 2.53%-29.69M | 24.90%-6.02M | -4.87%-9.08M | -7.86%-7.38M | -3.82%-7.2M |
Net non-operating interest income expense | 21.62%495K | 15.15%76K | 52.14%178K | 76.92%207K | -68.22%34K | 206.02%407K | -29.79%66K | 112.73%117K | 631.82%117K | 1,683.33%107K |
Non-operating interest income | 21.62%495K | ---- | ---- | ---- | -68.22%34K | 206.02%407K | ---- | ---- | ---- | 1,683.33%107K |
Total other finance cost | ---- | ---- | -52.14%-178K | -76.92%-207K | ---- | ---- | ---- | -112.73%-117K | -631.82%-117K | ---- |
Other net income (expense) | ||||||||||
Income before tax | 18.97%-23.73M | 22.52%-4.62M | 19.65%-7.2M | 14.82%-6.19M | 19.39%-5.72M | 3.45%-29.28M | 24.84%-5.96M | -4.19%-8.96M | -5.81%-7.27M | -2.37%-7.1M |
Income tax | ||||||||||
Net income | 18.97%-23.73M | 22.52%-4.62M | 19.65%-7.2M | 14.82%-6.19M | 19.39%-5.72M | 3.45%-29.28M | 24.84%-5.96M | -4.19%-8.96M | -5.81%-7.27M | -2.37%-7.1M |
Net income continuous Operations | 18.97%-23.73M | 22.52%-4.62M | 19.65%-7.2M | 14.82%-6.19M | 19.39%-5.72M | 3.45%-29.28M | 24.84%-5.96M | -4.19%-8.96M | -5.81%-7.27M | -2.37%-7.1M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 18.97%-23.73M | 22.52%-4.62M | 19.65%-7.2M | 14.82%-6.19M | 19.39%-5.72M | 3.45%-29.28M | 24.84%-5.96M | -4.19%-8.96M | -5.81%-7.27M | -2.37%-7.1M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 18.97%-23.73M | 22.52%-4.62M | 19.65%-7.2M | 14.82%-6.19M | 19.39%-5.72M | 3.45%-29.28M | 24.84%-5.96M | -4.19%-8.96M | -5.81%-7.27M | -2.37%-7.1M |
Basic earnings per share | 58.57%-3.94 | 63.03%-0.61 | 60.00%-1.06 | 64.71%-0.9 | 47.37%-1.5 | 31.09%-9.51 | 54.17%-1.65 | 32.05%-2.65 | 19.05%-2.55 | 9.52%-2.85 |
Diluted earnings per share | 58.57%-3.94 | 63.03%-0.61 | 60.00%-1.06 | 64.71%-0.9 | 47.37%-1.5 | 31.09%-9.51 | 54.17%-1.65 | 32.05%-2.65 | 19.05%-2.55 | 9.52%-2.85 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |